Article in BioWorld: Adrenomed readies for success as lead drug adrecizumab clears interim hurdle in sepsis trial
April 2019 by Cormac Sheridan, Staff Writer.
Hennigsdorf (Germany), May 6, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation at three upcoming conferences in Europe and the USA. Adrenomed representatives will be available for one-on-one meetings at
ISICEM, 39th International Symposium on Intensive Care and Emergency Medicine, March 19-22, 2019 | Brussels, Belgium Talk: March 21, 2019, at 8:30 – 8:45 AM CET, Salle M (Bozar) “The adrenomedullin antibody adrecizumab” during the
Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II
AdrenOSS-II trial continues as planned after positive interim efficacy analysis triggered by the treatment of 50% of randomized patients Proof-of-concept trial design testing Adrecizumab in early septic shock presented at International Symposium on Intensive Care